Lung Cancer Trial, Not Yet Recruiting NCT07590596 Sponsor: Sichuan Cancer Hospital and Research Institute Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Not Yet Recruiting

NCT07590596
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged 18 years or older.
  • People who have spots on their lungs (called pulmonary nodules) that doctors strongly suspect may be cancerous, based on clinical and imaging assessments.
  • People who have not yet received a confirmed diagnosis of lung cancer before enrolling in the trial.
  • People who are at a point in their care where more than one reasonable next step exists, such as surgery, further testing, or a period of monitoring.
  • People who are able to understand what the study involves and complete the study questionnaires.
  • People who are able and willing to sign a written consent form agreeing to take part.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People for whom there is only one clear management option for their lung nodule, meaning no real decision needs to be made.
  • People with serious cognitive difficulties or a significant history of severe psychiatric illness that could affect their ability to complete the questionnaires accurately.
  • People who are unable to communicate effectively with the study team.
  • People who do not wish to participate or who are unable to sign a written consent form.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 29 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xing Wei, MD, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China

Phone: +86 17302886627

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Sichuan Cancer Hospital and Research Institute
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
30 June 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Decisional Conflict Scale Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov